āĻšā§āĻŽALTME âĸ EPA
add
TME Pharma NV
ā§Ļ.ā§Ļā§Žā§¨âŦ
⧧⧍ āĻŽāĻžāϰā§āĻ, ā§Š:ā§Ļ⧍:ā§Ļā§ AM GMT +ā§§ · EUR · EPA · āĻĄāĻŋāϏāĻā§āϞā§āĻŽāĻžāϰ
āĻāĻžāϞ āĻļā§āώ āϝ⧠āĻĻāĻžāĻŽā§ āĻāĻŋāϞ
ā§Ļ.ā§Ļā§ā§ŦâŦ
āϏāĻžāϰāĻž āĻĻāĻŋāύā§āϰ āĻā§āϰā§āĻĄāĻŋāĻā§ā§ āϏā§āĻāĻā§āϰ āĻĻāĻžāĻŽā§āϰ āĻāĻ āĻž āύāĻžāĻŽāĻžāϰ āϰā§āĻā§āĻ
ā§Ļ.ā§Ļā§ā§âŦ - ā§Ļ.ā§Ļā§Žā§ŠâŦ
āϏāĻžāϰāĻž āĻŦāĻāϰā§āϰ āϰā§āĻā§āĻ
ā§Ļ.ā§Ļā§Ē⧝âŦ - ā§Ļ.ā§§ā§ĢâŦ
āĻŽāĻžāϰā§āĻā§āĻ āĻā§āϝāĻžāĻĒ
ā§ā§Ŧ.ā§Ģā§¯Â āϞāĻž EUR
āĻāĻĄāĻŧ āĻāϞāĻŋāĻāĻŽ
ā§Ģ.ā§ā§Ļ āϞāĻž
P/E āĻ
āύā§āĻĒāĻžāϤ
-
āϞāĻā§āϝāĻžāĻāĻļ āĻĒā§āϰāĻĻāĻžāύ
-
āĻĒā§āϰāĻžāĻāĻŽāĻžāϰāĻŋ āĻāĻā§āϏāĻā§āĻā§āĻ
EPA
āĻāĻŦāϰ⧠āϰā§ā§āĻā§
āĻĢāĻžāĻāύāĻžāύā§āϏāĻŋā§āĻžāϞ āĻĒāĻžāϰāĻĢāϰā§āĻŽā§āϝāĻžāύā§āϏ
āĻā§ā§āϰ āϏā§āĻā§āĻāĻŽā§āύā§āĻ
āĻāĻĒāĻžāϰā§āĻāύ
āύā§āĻ āĻāύāĻāĻžāĻŽ
| (EUR) | āĻā§āύ ⧍ā§Ļ⧍ā§Ģinfo | Y/Y āĻĒāϰāĻŋāĻŦāϰā§āϤāύ |
|---|---|---|
āĻāĻĒāĻžāϰā§āĻāύ | ā§§ā§Š.ā§Ģā§Ļ āĻšāĻž | â |
āĻŦā§āϝāĻŦāϏāĻž āĻāĻžāϞāĻžāύā§āϰ āĻāϰāĻ | ⧝.ā§Žā§¨Â āϞāĻž | -ā§¨ā§Ž.⧍ā§Ē% |
āύā§āĻ āĻāύāĻāĻžāĻŽ | -ā§§ā§Ļ.ā§Ģā§§Â āϞāĻž | ā§Šā§Ģ.ā§¨ā§Ž% |
āύā§āĻ āĻĒā§āϰāĻĢāĻŋāĻ āĻŽāĻžāϰā§āĻāĻŋāύ | -ā§.ā§ā§¯Â āĻšāĻž | â |
āĻļā§ā§āĻžāϰ āĻĒā§āϰāϤāĻŋ āĻāĻĒāĻžāϰā§āĻāύ | â | â |
EBITDA | -⧝.ā§Ŧā§Ģ āϞāĻž | ⧍ā§.ā§ā§Ē% |
āĻĒā§āϰāϝā§āĻā§āϝ āĻā§āϝāĻžāĻā§āϏā§āϰ āĻšāĻžāϰ | â | â |
āĻŦā§āϝāĻžāϞā§āύā§āϏ āĻļāĻŋāĻ
āĻŽā§āĻ āϏāĻŽā§āĻĒāĻĻ
āĻŽā§āĻ āĻĻāĻžā§
| (EUR) | āĻā§āύ ⧍ā§Ļ⧍ā§Ģinfo | Y/Y āĻĒāϰāĻŋāĻŦāϰā§āϤāύ |
|---|---|---|
āĻā§āϝāĻžāĻļ āĻ āĻāĻŽ āϏāĻŽā§ā§āϰ āĻŦāĻŋāύāĻŋā§ā§āĻ | ⧍ā§Ļ.ā§Ŧā§Ļ āϞāĻž | -ā§¨ā§Š.ā§ā§¯% |
āĻŽā§āĻ āϏāĻŽā§āĻĒāĻĻ | ⧍⧍.ā§¯ā§ŠÂ āϞāĻž | -⧍⧍.ā§Ļā§Ŧ% |
āĻŽā§āĻ āĻĻāĻžā§ | ā§¨ā§Ž.ā§Ŧā§ŠÂ āϞāĻž | ā§§ā§Ļā§Ž.⧍⧍% |
āĻŽā§āĻ āĻāĻā§āĻāĻāĻŋ | -ā§Ģ.ā§ā§Ļ āϞāĻž | â |
āĻāĻāĻāϏā§āĻā§āϝāĻžāύā§āĻĄāĻŋāĻ āĻļā§ā§āĻžāϰ | ⧝.ā§Ēā§§Â āĻā§ | â |
āĻĒā§āϰāĻžāĻāϏ āĻā§ āĻŦā§āĻ āϰā§āĻļāĻŋāĻ | -ā§.ā§Ŧā§Š | â |
āϏāĻŽā§āĻĒāĻĻ āĻĨā§āĻā§ āĻā§ | -ā§§ā§Ļā§Ģ.ā§Ģ⧝% | â |
āĻŽā§āϞāϧāύ āĻĨā§āĻā§ āĻā§ | -⧍⧧ā§Ļ.ā§Ģā§Ē% | â |
āĻā§āϝāĻžāĻļ āĻĢā§āϞā§
āύāĻāĻĻā§ āĻŽā§āĻ āĻĒāϰāĻŋāĻŦāϰā§āϤāύ
| (EUR) | āĻā§āύ ⧍ā§Ļ⧍ā§Ģinfo | Y/Y āĻĒāϰāĻŋāĻŦāϰā§āϤāύ |
|---|---|---|
āύā§āĻ āĻāύāĻāĻžāĻŽ | -ā§§ā§Ļ.ā§Ģā§§Â āϞāĻž | ā§Šā§Ģ.ā§¨ā§Ž% |
āĻ
āĻĒāĻžāϰā§āĻļāύ āĻĨā§āĻā§ āĻĒāĻžāĻā§āĻž āĻā§āϝāĻžāĻļ | -ā§§ā§Ē.ā§Šā§Ļ āϞāĻž | -ā§Ē.ā§Ģā§% |
āĻŦāĻŋāύāĻŋā§ā§āĻ āĻĨā§āĻā§ āĻĒā§āϰāĻžāĻĒā§āϤ āĻā§āϝāĻžāĻļ | ā§Ē.ā§Ļā§Ļ āĻšāĻž | ⧍ā§Ļā§Ļ.ā§Ļā§Ļ% |
āĻĢāĻžāĻāύā§āϝāĻžāύā§āϏāĻŋāĻ āĻĨā§āĻā§ āĻĒā§āϰāĻžāĻĒā§āϤ āĻā§āϝāĻžāĻļ | ā§Ž.ā§Šā§Ŧ āϞāĻž | -ā§Ēā§.ā§ā§Ž% |
āύāĻāĻĻā§ āĻŽā§āĻ āĻĒāϰāĻŋāĻŦāϰā§āϤāύ | -ā§Ģ.⧝ā§Ļ āϞāĻž | -ā§Šā§Ģā§.ā§Ŧā§Ē% |
āĻĢā§āϰāĻŋ āĻā§āϝāĻžāĻļ āĻĢā§āϞ⧠| -ā§Ŧ.ā§Ģā§Ŧ āϞāĻž | ⧝.ā§¨ā§Ž% |
āϏāĻŽā§āĻĒāϰā§āĻā§
TME Pharma, formerly NOXXON Pharma, is a biotechnology company founded in 1997 in Berlin, Germany which specialises on cancer treatment by targeting the tumor microenvironment. TME Pharma N.V. is listed on Euronext Growth, Paris and is a member of the German Association of Research-Based Pharmaceutical Companies, Verband forschender Arzneimittelhersteller.
TME Pharma develops drugs using technology yielding L-RNA molecules, which are of mirror-image configuration compared to naturally occurring D-RNA molecules. The company calls these agents Spiegelmers, from Spiegel, the German word for "mirror."
The L-RNA are resistant to the natural RNA nuclease enzymes. Wikipedia
āϏā§āĻĨāĻžāĻĒāĻŋāϤ āĻšā§ā§āĻā§
⧧⧝⧝ā§
āĻā§ā§āĻŦāϏāĻžāĻāĻ
āĻāϰā§āĻŽāĻāĻžāϰā§
⧧⧍